Synthetic Biology Patent Application Trends 2024

Synthetic Biology patent applications in 2024

Top Technology Areas in Synthetic Biology

Top CPC Codes

• C12N9/22 (No explanation available)
  • Count: 102 patents
  • Example: 20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation)
• C12N2310/20 (No explanation available)
  • Count: 96 patents
  • Example: 20240226339. Materials and Methods for Treatment of Hemoglobinopathies (Vertex Pharmaceuticals Incorporated)
• C12N15/11 (No explanation available)
  • Count: 46 patents
  • Example: 20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation)
• C12N15/907 (No explanation available)
  • Count: 34 patents
  • Example: 20240229077. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.)
• C12N15/102 (No explanation available)
  • Count: 27 patents
  • Example: 20240226339. Materials and Methods for Treatment of Hemoglobinopathies (Vertex Pharmaceuticals Incorporated)
• C12N15/111 (No explanation available)
  • Count: 27 patents
  • Example: 20240229024. COMPOSITIONS FOR GENOME EDITING (EmendoBio Inc.)
• C12N2800/80 (No explanation available)
  • Count: 27 patents
  • Example: 20240229077. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.)
• C12N15/113 (No explanation available)
  • Count: 18 patents
  • Example: 20240226339. Materials and Methods for Treatment of Hemoglobinopathies (Vertex Pharmaceuticals Incorporated)
• C12N15/86 (No explanation available)
  • Count: 17 patents
  • Example: 20240350666. COMPOSITIONS AND METHODS FOR HIGH EFFICIENCY GENOME EDITING (Children`s Medical Center Corporation)
• C12N15/63 (No explanation available)
  • Count: 14 patents
  • Example: 20240124877. RNA CLEAVAGE-INDUCED TRANSCRIPT STABILIZER AND USES THEREOF (Massachusetts Institute of Technology)

Top Companies in Synthetic Biology

INBIOSE N.V.

• Number of Synthetic Biology patents: 9
• Top CPC codes:
  • C12N9/1081 (No explanation available): 5 patents
  • C12P19/12 (No explanation available): 5 patents
  • C12N9/1051 (No explanation available): 5 patents
• Recent patents:
  • 20240191270. FERMENTATIVE PRODUCTION (INBIOSE N.V.) (20240613)
  • 20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.) (20240314)
  • 20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.) (20241003)

The General Hospital Corporation

• Number of Synthetic Biology patents: 7
• Top CPC codes:
  • C07K16/18 (No explanation available): 2 patents
  • A61P25/28 (No explanation available): 2 patents
  • C07K14/775 (No explanation available): 2 patents
• Recent patents:
  • 20240240207. Increasing Specificity for RNA-Guided Genome Editing (The General Hospital Corporation) (20240718)
  • 20240066102. Genome editing approaches to treat Spinal Muscular Atrophy (The General Hospital Corporation) (20240229)
  • 20240218334. Biosensors in Human Gut Organoids (The General Hospital Corporation) (20240704)

Fate Therapeutics, Inc.

• Number of Synthetic Biology patents: 6
• Top CPC codes:
  • A61K39/4631 (No explanation available): 5 patents
  • A61K39/4611 (No explanation available): 4 patents
  • A61P35/00 (No explanation available): 4 patents
• Recent patents:
  • 20240307540. PROTECTED EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES (Fate Therapeutics, Inc.) (20240919)
  • 20240131156. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF (Fate Therapeutics, Inc.) (20240425)
  • 20240033355. ENGINEERED iPSC AND ARMED IMMUNE EFFECTOR CELLS (Fate Therapeutics, Inc.) (20240201)

PRIME MEDICINE, INC.

• Number of Synthetic Biology patents: 4
• Top CPC codes:
  • C12N2310/20 (No explanation available): 4 patents
  • C12N9/22 (No explanation available): 2 patents
  • C12N15/11 (No explanation available): 2 patents
• Recent patents:
  • 20240229038. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE (PRIME MEDICINE, INC.) (20240711)
  • 20240301444. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS (PRIME MEDICINE, INC.) (20240912)
  • 20240167026. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE (PRIME MEDICINE, INC.) (20240523)

The Broad Institute, Inc.

• Number of Synthetic Biology patents: 4
• Top CPC codes:
  • C12N15/111 (No explanation available): 4 patents
  • C12N15/907 (No explanation available): 3 patents
  • C12N9/1276 (No explanation available): 3 patents
• Recent patents:
  • 20240117382. DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF CRISPR SYSTEMS AND COMPOSITIONS FOR GENOME EDITING AS TO HEMATOPOIETIC STEM CELLS (HSCs) (The Broad Institute, Inc.) (20240411)
  • 20240158779. METHODS AND COMPOSITIONS FOR SIMULTANEOUS EDITING OF BOTH STRANDS OF A TARGET DOUBLE-STRANDED NUCLEOTIDE SEQUENCE (The Broad Institute, Inc.) (20240516)
  • 20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.) (20241003)

Massachusetts Institute of Technology

• Number of Synthetic Biology patents: 4
• Top CPC codes:
  • C12N2310/20 (No explanation available): 3 patents
  • C12N9/22 (No explanation available): 2 patents
  • C12N15/11 (No explanation available): 2 patents
• Recent patents:
  • 20240301373. FANZORS ARE RNA-GUIDED NUCLEASES ENCODED IN EUKARYOTIC GENOMES (Massachusetts Institute of Technology) (20240912)
  • 20240067957. AUTOCATALYTIC BASE EDITING FOR RNA-RESPONSIVE TRANSLATIONAL CONTROL (Massachusetts Institute of Technology) (20240229)
  • 20240035008. GENOMIC EDITING WITH SITE-SPECIFIC RETROTRANSPOSONS (Massachusetts Institute of Technology) (20240201)

The Board of Trustees of the Leland Stanford Junior University

• Number of Synthetic Biology patents: 4
• Top CPC codes:
  • C12N2310/20 (No explanation available): 4 patents
  • C12N9/22 (No explanation available): 3 patents
  • C12N15/907 (No explanation available): 2 patents
• Recent patents:
  • 20240263173. HIGH-THROUGHPUT PRECISION GENOME EDITING IN HUMAN CELLS (The Board of Trustees of the Leland Stanford Junior University) (20240808)
  • 20240401034. Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Correction (The Board of Trustees of the Leland Stanford Junior University) (20241205)
  • 20240018493. KNOCK-IN OF LARGE DNA FOR LONG-TERM HIGH GENOMIC EXPRESSION (The Board of Trustees of the Leland Stanford Junior University) (20240118)

UNIVERSITY OF MASSACHUSETTS

• Number of Synthetic Biology patents: 4
• Top CPC codes:
  • C12N9/22 (No explanation available): 3 patents
  • C12N2310/20 (No explanation available): 3 patents
  • C12N15/907 (No explanation available): 2 patents
• Recent patents:
  • 20240141359. GENOME EDITING FOR TREATING MUSCULAR DYSTROPHY (UNIVERSITY OF MASSACHUSETTS) (20240502)
  • 20240167029. MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING (UNIVERSITY OF MASSACHUSETTS) (20240523)
  • 20240036027. Nanopore Biosensors and Uses Thereof (UNIVERSITY OF MASSACHUSETTS) (20240201)

Wisconsin Alumni Research Foundation

• Number of Synthetic Biology patents: 3
• Top CPC codes:
  • A61K35/17 (No explanation available): 2 patents
  • A61K39/4611 (No explanation available): 2 patents
  • A61K39/4631 (No explanation available): 2 patents
• Recent patents:
  • 20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation) (20240711)
  • 20240131066. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation) (20240425)
  • 20240026466. CELL-BASED DNA SENSORS AND METHODS OF USING SAME (Wisconsin Alumni Research Foundation) (20240125)

Prime Medicine, Inc.

• Number of Synthetic Biology patents: 3
• Top CPC codes:
  • C12N9/22 (No explanation available): 3 patents
  • C12N9/1276 (No explanation available): 2 patents
  • C12N2310/20 (No explanation available): 2 patents
• Recent patents:
  • 20240352453. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF RETINOPATHY (Prime Medicine, Inc.) (20241024)
  • 20240376466. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF FANCONI ANEMIA (Prime Medicine, Inc.) (20241114)
  • 20240360476. Genome Editing Compositions and Methods for Treatment of Myotonic Dystrophy (Prime Medicine, Inc.) (20241031)

New Companies in Synthetic Biology (Last Month)

800px

No new companies detected in the last month.

Emerging Technology Areas in Synthetic Biology

• G01N27/44704 (No explanation available)
  • Count: 1 patents
  • Example: 20240044837. BIOSENSOR (Taiwan Semiconductor Manufacturing Company, Ltd.)
• B03C5/005 (No explanation available)
  • Count: 1 patents
  • Example: 20240044837. BIOSENSOR (Taiwan Semiconductor Manufacturing Company, Ltd.)
• G01N27/44782 (No explanation available)
  • Count: 1 patents
  • Example: 20240044837. BIOSENSOR (Taiwan Semiconductor Manufacturing Company, Ltd.)
• A61P25/00 (No explanation available)
  • Count: 1 patents
  • Example: 20240043830. MULTIPLEX EPIGENOME EDITING (The Trustees of Columbia University in the City of New York)
• G16B50/30 (No explanation available)
  • Count: 1 patents
  • Example: 20240320462. Biocomputing platform and Boolean logic gates (Regents of the University of Minnesota)
• G06N3/002 (No explanation available)
  • Count: 1 patents
  • Example: 20240320462. Biocomputing platform and Boolean logic gates (Regents of the University of Minnesota)
• G01N33/02 (No explanation available)
  • Count: 1 patents
  • Example: 20240319126. MULTI-SCALE, NANO- TO MESOSTRUCTURAL ENGINEERING OF SILK BIOPOLYMER-INTERLAYER BIOSENSORS FOR CONTINUOUS CO-MONITORING OF NUTRIENTS IN FOOD (The Regents of the University of California)
• G01N27/227 (No explanation available)
  • Count: 1 patents
  • Example: 20240319126. MULTI-SCALE, NANO- TO MESOSTRUCTURAL ENGINEERING OF SILK BIOPOLYMER-INTERLAYER BIOSENSORS FOR CONTINUOUS CO-MONITORING OF NUTRIENTS IN FOOD (The Regents of the University of California)
• G01N27/221 (No explanation available)
  • Count: 1 patents
  • Example: 20240319126. MULTI-SCALE, NANO- TO MESOSTRUCTURAL ENGINEERING OF SILK BIOPOLYMER-INTERLAYER BIOSENSORS FOR CONTINUOUS CO-MONITORING OF NUTRIENTS IN FOOD (The Regents of the University of California)
• C12Y303/01001 (No explanation available)
  • Count: 1 patents
  • Example: 20240318209. GENETICALLY ENGINEERED BACTERIUM USING GLUCOSE AS SUBSTRATE FOR DE NOVO SYNTHESIS OF VANILLIN AND APPLICATION THEREOF (Beijing University of Chemical Technology)

Top Companies in Emerging Synthetic Biology Technologies

• The Regents of the University of California: 3 patents
• Taiwan Semiconductor Manufacturing Company, Ltd.: 3 patents
• Regents of the University of Minnesota: 2 patents
• Beijing University of Chemical Technology: 1 patents
• The Trustees of Columbia University in the City of New York: 1 patents

Top Inventors in Synthetic Biology

Joeri Beauprez

• Number of Synthetic Biology patents: 9
• Top companies:
  • INBIOSE N.V.: 9 patents
• Recent patents:
  • 20240191270. FERMENTATIVE PRODUCTION (INBIOSE N.V.) (20240613)
  • 20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.) (20240314)
  • 20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.) (20241003)

Bahram VALAMEHR of San Diego CA (US)

• Number of Synthetic Biology patents: 6
• Top companies:
  • Fate Therapeutics, Inc.: 6 patents
• Recent patents:
  • 20240307540. PROTECTED EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES (Fate Therapeutics, Inc.) (20240919)
  • 20240131156. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF (Fate Therapeutics, Inc.) (20240425)
  • 20240033355. ENGINEERED iPSC AND ARMED IMMUNE EFFECTOR CELLS (Fate Therapeutics, Inc.) (20240201)

David R. Liu of Cambridge MA (US)

• Number of Synthetic Biology patents: 5
• Top companies:
  • The Broad Institute, Inc.: 3 patents
  • President and Fellows of Harvard College: 2 patents
• Recent patents:
  • 20240271116. SUPPRESSION OF PAIN BY GENE EDITING (President and Fellows of Harvard College) (20240815)
  • 20240209329. PROGRAMMABLE CAS9-RECOMBINASE FUSION PROTEINS AND USES THEREOF (President and Fellows of Harvard College) (20240627)
  • 20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.) (20241003)

Pieter Coussement

• Number of Synthetic Biology patents: 5
• Top companies:
  • INBIOSE N.V.: 5 patents
• Recent patents:
  • 20240368651. CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES (INBIOSE N.V.) (20241107)
  • 20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.) (20240627)
  • 20240191270. FERMENTATIVE PRODUCTION (INBIOSE N.V.) (20240613)

Thomas Decoene

• Number of Synthetic Biology patents: 5
• Top companies:
  • INBIOSE N.V.: 5 patents
• Recent patents:
  • 20240368651. CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES (INBIOSE N.V.) (20241107)
  • 20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.) (20240627)
  • 20240191270. FERMENTATIVE PRODUCTION (INBIOSE N.V.) (20240613)

Annelies Vercauteren

• Number of Synthetic Biology patents: 5
• Top companies:
  • INBIOSE N.V.: 5 patents
• Recent patents:
  • 20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.) (20240627)
  • 20240035004. VARIANT SUCROSE PERMEASE POLYPEPTIDES (INBIOSE N.V.) (20240201)
  • 20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.) (20241003)

Ryan BJORDAHL of San Diego CA (US)

• Number of Synthetic Biology patents: 4
• Top companies:
  • Fate Therapeutics, Inc.: 4 patents
• Recent patents:
  • 20240115602. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF (Fate Therapeutics, Inc.) (20240411)
  • 20240307540. PROTECTED EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES (Fate Therapeutics, Inc.) (20240919)
  • 20240131156. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF (Fate Therapeutics, Inc.) (20240425)

Jode GOODRIDGE of San Diego CA (US)

• Number of Synthetic Biology patents: 4
• Top companies:
  • Fate Therapeutics, Inc.: 4 patents
• Recent patents:
  • 20240115602. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF (Fate Therapeutics, Inc.) (20240411)
  • 20240307540. PROTECTED EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES (Fate Therapeutics, Inc.) (20240919)
  • 20240131156. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF (Fate Therapeutics, Inc.) (20240425)

Kristof Vandewalle

• Number of Synthetic Biology patents: 4
• Top companies:
  • INBIOSE N.V.: 4 patents
• Recent patents:
  • 20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.) (20240627)
  • 20240035004. VARIANT SUCROSE PERMEASE POLYPEPTIDES (INBIOSE N.V.) (20240201)
  • 20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.) (20241003)

Tom Tong LEE of San Diego CA (US)

• Number of Synthetic Biology patents: 3
• Top companies:
  • Fate Therapeutics, Inc.: 3 patents
• Recent patents:
  • 20240226293. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF (Fate Therapeutics, Inc.) (20240711)
  • 20240115602. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF (Fate Therapeutics, Inc.) (20240411)
  • 20240131156. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF (Fate Therapeutics, Inc.) (20240425)

Wei Hsi YEH of Cambridge MA (US)

• Number of Synthetic Biology patents: 3
• Top companies:
  • PRIME MEDICINE, INC.: 2 patents
  • Prime Medicine, Inc.: 1 patents
• Recent patents:
  • 20240229038. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE (PRIME MEDICINE, INC.) (20240711)
  • 20240352453. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF RETINOPATHY (Prime Medicine, Inc.) (20241024)
  • 20240167026. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE (PRIME MEDICINE, INC.) (20240523)

Aaron Nakwon CHANG of Lexington MA (US)

• Number of Synthetic Biology patents: 3
• Top companies:
  • PRIME MEDICINE, INC.: 3 patents
• Recent patents:
  • 20240229038. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE (PRIME MEDICINE, INC.) (20240711)
  • 20240301444. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS (PRIME MEDICINE, INC.) (20240912)
  • 20240167026. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE (PRIME MEDICINE, INC.) (20240523)

Andrew Vito Anzalone of Cambridge MA (US)

• Number of Synthetic Biology patents: 3
• Top companies:
  • The Broad Institute, Inc.: 3 patents
• Recent patents:
  • 20240229077. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.) (20240711)
  • 20240158779. METHODS AND COMPOSITIONS FOR SIMULTANEOUS EDITING OF BOTH STRANDS OF A TARGET DOUBLE-STRANDED NUCLEOTIDE SEQUENCE (The Broad Institute, Inc.) (20240516)
  • 20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.) (20241003)

Roman Lvovitch BOGORAD of South Boston MA (US)

• Number of Synthetic Biology patents: 3
• Top companies:
  • CRISPR Therapeutics AG: 2 patents
  • CRISPR THERAPEUTICS AG: 1 patents
• Recent patents:
  • 20240229078. MATERIALS AND METHODS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE 1A (CRISPR THERAPEUTICS AG) (20240711)
  • 20240175014. MATERIALS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY (CRISPR Therapeutics AG) (20240530)
  • 20240167060. COMPOSITIONS AND METHODS FOR GENOMIC EDITING BY INSERTION OF DONOR POLYNUCLEOTIDES (CRISPR Therapeutics AG) (20240523)

Dewi HARJANTO of Brookline MA (US)

• Number of Synthetic Biology patents: 3
• Top companies:
  • Prime Medicine, Inc.: 2 patents
  • PRIME MEDICINE, INC.: 1 patents
• Recent patents:
  • 20240352453. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF RETINOPATHY (Prime Medicine, Inc.) (20241024)
  • 20240301444. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS (PRIME MEDICINE, INC.) (20240912)
  • 20240376466. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF FANCONI ANEMIA (Prime Medicine, Inc.) (20241114)

Sofie Aesaert

• Number of Synthetic Biology patents: 3
• Top companies:
  • INBIOSE N.V.: 3 patents
• Recent patents:
  • 20240368651. CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES (INBIOSE N.V.) (20241107)
  • 20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.) (20240627)
  • 20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.) (20241003)

Gert Peters

• Number of Synthetic Biology patents: 3
• Top companies:
  • INBIOSE N.V.: 3 patents
• Recent patents:
  • 20240368651. CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES (INBIOSE N.V.) (20241107)
  • 20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.) (20240627)
  • 20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.) (20241003)

Jin-Soo Kim

• Number of Synthetic Biology patents: 3
• Top companies:
  • TOOLGEN INCORPORATED: 3 patents
• Recent patents:
  • 20240052356. Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells (TOOLGEN INCORPORATED) (20240215)
  • 20240240192. Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells (TOOLGEN INCORPORATED) (20240718)
  • 20240026367. Compositions Comprising Cas9/guide RNA Complexes for Inducing Targeted Disruption of Endogenous Genes in Eukaryotic Cells (TOOLGEN INCORPORATED) (20240125)

Seung Woo Cho

• Number of Synthetic Biology patents: 3
• Top companies:
  • TOOLGEN INCORPORATED: 3 patents
• Recent patents:
  • 20240052356. Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells (TOOLGEN INCORPORATED) (20240215)
  • 20240240192. Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells (TOOLGEN INCORPORATED) (20240718)
  • 20240026367. Compositions Comprising Cas9/guide RNA Complexes for Inducing Targeted Disruption of Endogenous Genes in Eukaryotic Cells (TOOLGEN INCORPORATED) (20240125)

Sojung Kim

• Number of Synthetic Biology patents: 3
• Top companies:
  • TOOLGEN INCORPORATED: 3 patents
• Recent patents:
  • 20240052356. Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells (TOOLGEN INCORPORATED) (20240215)
  • 20240240192. Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells (TOOLGEN INCORPORATED) (20240718)
  • 20240026367. Compositions Comprising Cas9/guide RNA Complexes for Inducing Targeted Disruption of Endogenous Genes in Eukaryotic Cells (TOOLGEN INCORPORATED) (20240125)

Krishanu Saha of Madison WI (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • Wisconsin Alumni Research Foundation: 2 patents
• Recent patents:
  • 20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation) (20240711)
  • 20240131066. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation) (20240425)

Lauren Sarko of Middleton WI (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • Wisconsin Alumni Research Foundation: 2 patents
• Recent patents:
  • 20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation) (20240711)
  • 20240131066. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation) (20240425)

Ante Sven Lundberg of Cambridge MA (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • Vertex Pharmaceuticals Incorporated: 1 patents
  • Vertex Phamaceuticals Incorporated: 1 patents
• Recent patents:
  • 20240226339. Materials and Methods for Treatment of Hemoglobinopathies (Vertex Pharmaceuticals Incorporated) (20240711)
  • 20240066150. MATERIALS AND METHODS FOR TREATMENT OF PAIN RELATED DISORDERS (Vertex Phamaceuticals Incorporated) (20240229)

Chase Lawrence Beisel of Raleigh NC (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • North Carolina State University: 2 patents
• Recent patents:
  • 20240229012. SITE-SPECIFIC GENOME MODIFICATION TECHNOLOGY (North Carolina State University) (20240711)
  • 20240132873. SITE-SPECIFIC GENOME MODIFICATION TECHNOLOGY (North Carolina State University) (20240425)

Scott Patrick Collins of Raleigh NC (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • North Carolina State University: 2 patents
• Recent patents:
  • 20240229012. SITE-SPECIFIC GENOME MODIFICATION TECHNOLOGY (North Carolina State University) (20240711)
  • 20240132873. SITE-SPECIFIC GENOME MODIFICATION TECHNOLOGY (North Carolina State University) (20240425)

David Baram

• Number of Synthetic Biology patents: 2
• Top companies:
  • EmendoBio Inc.: 2 patents
• Recent patents:
  • 20240229024. COMPOSITIONS FOR GENOME EDITING (EmendoBio Inc.) (20240711)
  • 20240132884. COMPOSITIONS FOR GENOME EDITING (EmendoBio Inc.) (20240425)

Lior Izhar

• Number of Synthetic Biology patents: 2
• Top companies:
  • EmendoBio Inc.: 2 patents
• Recent patents:
  • 20240229024. COMPOSITIONS FOR GENOME EDITING (EmendoBio Inc.) (20240711)
  • 20240132884. COMPOSITIONS FOR GENOME EDITING (EmendoBio Inc.) (20240425)

Rafi Emmanuel

• Number of Synthetic Biology patents: 2
• Top companies:
  • EmendoBio Inc.: 2 patents
• Recent patents:
  • 20240229024. COMPOSITIONS FOR GENOME EDITING (EmendoBio Inc.) (20240711)
  • 20240132884. COMPOSITIONS FOR GENOME EDITING (EmendoBio Inc.) (20240425)

Jonathan M. LEVY of Brookline MA (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • PRIME MEDICINE, INC.: 2 patents
• Recent patents:
  • 20240229038. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE (PRIME MEDICINE, INC.) (20240711)
  • 20240167026. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE (PRIME MEDICINE, INC.) (20240523)

Yuan WANG

• Number of Synthetic Biology patents: 2
• Top companies:
  • BEIJING INSTITUTE OF HEART, LUNG AND BLOOD VESSEL DISEASES: 1 patents
  • HUAZHONG AGRICULTURAL UNIVERSITY: 1 patents
• Recent patents:
  • 20240229045. APTAMER FOR SPECIFICALLY RECOGNIZING SOLUBLE ST2 PROTEIN AND APPLICATION OF THE SAME (BEIJING INSTITUTE OF HEART, LUNG AND BLOOD VESSEL DISEASES) (20240711)
  • 20240368675. PAM-LESS ENDONUCLEASE AND GENE EDITING SYSTEM MEDIATED BY PAM-LESS ENDONUCLEASE (HUAZHONG AGRICULTURAL UNIVERSITY) (20241107)

James William Nelson of Cambridge MA (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • The Broad Institute, Inc.: 2 patents
• Recent patents:
  • 20240229077. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.) (20240711)
  • 20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.) (20241003)

Chad Albert COWAN of South Boston MA (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • CRISPR THERAPEUTICS AG: 1 patents
  • CRISPR Therapeutics AG: 1 patents
• Recent patents:
  • 20240229078. MATERIALS AND METHODS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE 1A (CRISPR THERAPEUTICS AG) (20240711)
  • 20240175014. MATERIALS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY (CRISPR Therapeutics AG) (20240530)

Ante Sven LUNDBERG of South Boston MA (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • CRISPR THERAPEUTICS AG: 1 patents
  • CRISPR Therapeutics AG: 1 patents
• Recent patents:
  • 20240229078. MATERIALS AND METHODS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE 1A (CRISPR THERAPEUTICS AG) (20240711)
  • 20240175014. MATERIALS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY (CRISPR Therapeutics AG) (20240530)

Rasmus O. Bak of Stanford CA (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • The Board of Trustees of the Leland Stanford Junior University: 2 patents
• Recent patents:
  • 20240124895. NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLS AND RELATED KITS (The Board of Trustees of the Leland Stanford Junior University) (20240418)
  • 20240401034. Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Correction (The Board of Trustees of the Leland Stanford Junior University) (20241205)

Ayal Hendel of Stanford CA (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • The Board of Trustees of the Leland Stanford Junior University: 2 patents
• Recent patents:
  • 20240124895. NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLS AND RELATED KITS (The Board of Trustees of the Leland Stanford Junior University) (20240418)
  • 20240401034. Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Correction (The Board of Trustees of the Leland Stanford Junior University) (20241205)

Matthew H. Porteus of Stanford CA (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • The Board of Trustees of the Leland Stanford Junior University: 2 patents
• Recent patents:
  • 20240124895. NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLS AND RELATED KITS (The Board of Trustees of the Leland Stanford Junior University) (20240418)
  • 20240401034. Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Correction (The Board of Trustees of the Leland Stanford Junior University) (20241205)

Michael Andreas Kock

• Number of Synthetic Biology patents: 2
• Top companies:
  • INARI AGRICULTURE TECHNOLOGY, INC.: 2 patents
• Recent patents:
  • 20240294937. GENOME EDITING OF TRANSGENIC CROP PLANTS WITH MODIFIED TRANSGENIC LOCI (INARI AGRICULTURE TECHNOLOGY, INC.) (20240905)
  • 20240011043. GENERATION OF PLANTS WITH IMPROVED TRANSGENIC LOCI BY GENOME EDITING (INARI AGRICULTURE TECHNOLOGY, INC.) (20240111)

Michael Lee Nuccio of Salem NH (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • INARI AGRICULTURE TECHNOLOGY, INC.: 2 patents
• Recent patents:
  • 20240294937. GENOME EDITING OF TRANSGENIC CROP PLANTS WITH MODIFIED TRANSGENIC LOCI (INARI AGRICULTURE TECHNOLOGY, INC.) (20240905)
  • 20240011043. GENERATION OF PLANTS WITH IMPROVED TRANSGENIC LOCI BY GENOME EDITING (INARI AGRICULTURE TECHNOLOGY, INC.) (20240111)

Frédéric Van Ex

• Number of Synthetic Biology patents: 2
• Top companies:
  • INARI AGRICULTURE TECHNOLOGY, INC.: 2 patents
• Recent patents:
  • 20240294937. GENOME EDITING OF TRANSGENIC CROP PLANTS WITH MODIFIED TRANSGENIC LOCI (INARI AGRICULTURE TECHNOLOGY, INC.) (20240905)
  • 20240011043. GENERATION OF PLANTS WITH IMPROVED TRANSGENIC LOCI BY GENOME EDITING (INARI AGRICULTURE TECHNOLOGY, INC.) (20240111)

Alexandra Elata of Arlington MA (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • INARI AGRICULTURE TECHNOLOGY, INC.: 2 patents
• Recent patents:
  • 20240294937. GENOME EDITING OF TRANSGENIC CROP PLANTS WITH MODIFIED TRANSGENIC LOCI (INARI AGRICULTURE TECHNOLOGY, INC.) (20240905)
  • 20240011043. GENERATION OF PLANTS WITH IMPROVED TRANSGENIC LOCI BY GENOME EDITING (INARI AGRICULTURE TECHNOLOGY, INC.) (20240111)

Daniel Rodriguez Leal of Raleigh NC (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • INARI AGRICULTURE TECHNOLOGY, INC.: 2 patents
• Recent patents:
  • 20240294937. GENOME EDITING OF TRANSGENIC CROP PLANTS WITH MODIFIED TRANSGENIC LOCI (INARI AGRICULTURE TECHNOLOGY, INC.) (20240905)
  • 20240011043. GENERATION OF PLANTS WITH IMPROVED TRANSGENIC LOCI BY GENOME EDITING (INARI AGRICULTURE TECHNOLOGY, INC.) (20240111)

Joshua L. Price of Cambridge MA (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • INARI AGRICULTURE TECHNOLOGY, INC.: 2 patents
• Recent patents:
  • 20240294937. GENOME EDITING OF TRANSGENIC CROP PLANTS WITH MODIFIED TRANSGENIC LOCI (INARI AGRICULTURE TECHNOLOGY, INC.) (20240905)
  • 20240011043. GENERATION OF PLANTS WITH IMPROVED TRANSGENIC LOCI BY GENOME EDITING (INARI AGRICULTURE TECHNOLOGY, INC.) (20240111)

Sofie De Maeseneire

• Number of Synthetic Biology patents: 2
• Top companies:
  • INBIOSE N.V.: 2 patents
• Recent patents:
  • 20240294958. EXTRACELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.) (20240905)
  • 20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.) (20240314)

Yatti De Nijs

• Number of Synthetic Biology patents: 2
• Top companies:
  • INBIOSE N.V.: 2 patents
• Recent patents:
  • 20240294958. EXTRACELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.) (20240905)
  • 20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.) (20240314)

Tom Delmulle

• Number of Synthetic Biology patents: 2
• Top companies:
  • INBIOSE N.V.: 2 patents
• Recent patents:
  • 20240294958. EXTRACELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.) (20240905)
  • 20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.) (20240314)

Yakeel T. Quiroz of Charlestown MA (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • The General Hospital Corporation: 2 patents
• Recent patents:
  • 20240287165. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF (The General Hospital Corporation) (20240829)
  • 20240301044. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF (The General Hospital Corporation) (20240912)

Joseph F. Arboleda-Velasquez of Newton MA (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • The General Hospital Corporation: 2 patents
• Recent patents:
  • 20240287165. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF (The General Hospital Corporation) (20240829)
  • 20240301044. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF (The General Hospital Corporation) (20240912)

Eric Reiman of Phoenix AZ (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • The General Hospital Corporation: 2 patents
• Recent patents:
  • 20240287165. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF (The General Hospital Corporation) (20240829)
  • 20240301044. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF (The General Hospital Corporation) (20240912)

Francisco Lopera

• Number of Synthetic Biology patents: 2
• Top companies:
  • The General Hospital Corporation: 2 patents
• Recent patents:
  • 20240287165. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF (The General Hospital Corporation) (20240829)
  • 20240301044. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF (The General Hospital Corporation) (20240912)

Radwanul Hasan SIDDIQUE of Monrovia CA (US)

• Number of Synthetic Biology patents: 2
• Top companies:
  • Samsung Electronics Co., Ltd.: 2 patents
• Recent patents:
  • 20240350024. POLARIZED PHOTOPLETHYSMOGRAPHY (PPG) BIOSENSORS, ARRAYS AND SYSTEMS (Samsung Electronics Co., Ltd.) (20241024)
  • 20240065566. POLARIZED PHOTOPLETHYSMOGRAPHY (PPG) BIOSENSORS, ARRAYS AND SYSTEMS (Samsung Electronics Co., Ltd.) (20240229)

Top Collaborations in Synthetic Biology

Top US States for Synthetic Biology Inventors

Top Cities for Synthetic Biology Inventors

• Cambridge: 81 inventors
• Zwijnaarde: 43 inventors
• San Diego: 37 inventors
• Beijing: 18 inventors
• South Boston: 18 inventors
• Boston: 16 inventors
• Seoul: 16 inventors
• Wuhan: 15 inventors
• Stanford: 14 inventors
• Seattle: 14 inventors
• San Francisco: 13 inventors
• Chicago: 10 inventors
• Irvine: 10 inventors
• Durham: 10 inventors
• Raleigh: 8 inventors
• Brookline: 8 inventors
• Burlington: 8 inventors
• Madison: 7 inventors
• Alameda: 7 inventors
• Boise: 7 inventors